Randomized controlled trial of dapagliflozin combined with shakubatravalsartan in improving cardiac function in patients with non-type 2 diabetic chronic heart failure
Objective To explore the clinical efficacy of dapagliflozin combined with shakubatrivasartan in the treatment of chronic heart failure(CHF)in patients with non-type 2 diabetes mellitus.Methods 95 patients with chronic heart failure admitted to the Cardiovascular Department of Bengbu First People's Hospital from February 2022 to May 2023 were randomly divided into observation group(47 cases)and control group(48 cases).The control group was treated with shakubatravalsartan,and the observation group was treated with dapagliflozin on the basis of the control group.The two groups were treated for 3 months.The cardiac function,NT-proBNP,left atrial diameter,serum uric acid and fasting glucose changes before and after treatment and the incidence of adverse reactions were compared between the two groups.Results There was no significant difference in age,sex,body mass index,heart rate,EF value,NT-proBNP,left atrial diameter,fasting blood glucose,triglyceride,cholesterol,HDL-C,LDL-C and creatinine between the two groups before treatment(P＞0.05).After 3 months of treatment,the serum uric acid,NT-proBNP and left atrial diameter in the observation group were lower than those in the control group,with statistical significance(P＜0.05);he left ventricular EF value was higher than that of the control group,and the difference was statistically significant(P＜0.05);there was no significant difference in fasting blood glucose changes between the two groups(P＞0.05).The total incidence of adverse reactions in the observation group(6.38%)was slightly higher than that in the control group(6.25%),with no statistical significance(P＞0.05).Conclusion Dapagliflozin can effectively improve the cardiac function of chronic heart failure patients with non-type 2 diabetes mellitus,which is safe and effective with few adverse reactions.
NETL
NSTL
万方数据
